Department of Breast Surgery, Imperial College Healthcare NHS Trust, London, UK.
Department of Breast Surgery, Imperial College Healthcare NHS Trust, London, UK; BioSurgery and Surgical Technology, Department of Surgery, Imperial College London, London, UK.
Lancet Oncol. 2022 May;23(5):682-690. doi: 10.1016/S1470-2045(22)00145-0. Epub 2022 Apr 7.
Radiotherapy before mastectomy and autologous free-flap breast reconstruction can avoid adverse radiation effects on healthy donor tissues and delays to adjuvant radiotherapy. However, evidence for this treatment sequence is sparse. We aimed to explore the feasibility of preoperative radiotherapy followed by skin-sparing mastectomy and deep inferior epigastric perforator (DIEP) flap reconstruction in patients with breast cancer requiring mastectomy.
We conducted a prospective, non-randomised, feasibility study at two National Health Service trusts in the UK. Eligible patients were women aged older than 18 years with a laboratory diagnosis of primary breast cancer requiring mastectomy and post-mastectomy radiotherapy, who were suitable for DIEP flap reconstruction. Preoperative radiotherapy started 3-4 weeks after neoadjuvant chemotherapy and was delivered to the breast, plus regional nodes as required, at 40 Gy in 15 fractions (over 3 weeks) or 42·72 Gy in 16 fractions (over 3·2 weeks). Adverse skin radiation toxicity was assessed preoperatively using the Radiation Therapy Oncology Group toxicity grading system. Skin-sparing mastectomy and DIEP flap reconstruction were planned for 2-6 weeks after completion of preoperative radiotherapy. The primary endpoint was the proportion of open breast wounds greater than 1 cm width requiring a dressing at 4 weeks after surgery, assessed in all participants. This study is registered with ClinicalTrials.gov, NCT02771938, and is closed to recruitment.
Between Jan 25, 2016, and Dec 11, 2017, 33 patients were enrolled. At 4 weeks after surgery, four (12·1%, 95% CI 3·4-28·2) of 33 patients had an open breast wound greater than 1 cm. One (3%) patient had confluent moist desquamation (grade 3). There were no serious treatment-related adverse events and no treatment-related deaths.
Preoperative radiotherapy followed by skin-sparing mastectomy and immediate DIEP flap reconstruction is feasible and technically safe, with rates of breast open wounds similar to those reported with post-mastectomy radiotherapy. A randomised trial comparing preoperative radiotherapy with post-mastectomy radiotherapy is required to precisely determine and compare surgical, oncological, and breast reconstruction outcomes, including quality of life.
Cancer Research UK, National Institute for Health Research.
在乳房切除术和自体游离皮瓣乳房重建之前进行放疗可以避免健康供体组织受到辐射的不良影响,并延迟辅助放疗。然而,这种治疗顺序的证据很少。我们旨在探讨在需要乳房切除术的乳腺癌患者中,术前放疗继以保留皮肤的乳房切除术和腹壁下动脉穿支皮瓣(DIEP)重建的可行性。
我们在英国的两个国民保健服务信托基金中进行了一项前瞻性、非随机、可行性研究。合格的患者为年龄大于 18 岁的女性,实验室诊断为原发性乳腺癌,需要乳房切除术和乳房切除术后放疗,适合 DIEP 皮瓣重建。术前放疗在新辅助化疗后 3-4 周开始,对乳房和区域淋巴结进行 40 Gy 15 次(3 周内)或 42.72 Gy 16 次(3.2 周内)照射。术前使用放射治疗肿瘤学组毒性分级系统评估皮肤放射性毒性。术前放疗完成后 2-6 周计划进行保留皮肤的乳房切除术和 DIEP 皮瓣重建。主要终点是所有参与者术后 4 周时大于 1 厘米宽度的开放性乳房伤口的比例,需要敷料治疗。本研究在 ClinicalTrials.gov 注册,NCT02771938,现已关闭入组。
2016 年 1 月 25 日至 2017 年 12 月 11 日期间,共纳入 33 例患者。术后 4 周时,33 例患者中有 4 例(12.1%,95%CI 3.4-28.2)的乳房伤口大于 1 厘米。1 例(3%)患者出现融合性湿性脱皮(3 级)。无严重治疗相关不良事件和治疗相关死亡。
术前放疗继以保留皮肤的乳房切除术和即刻 DIEP 皮瓣重建是可行的,技术上是安全的,乳房开放性伤口的发生率与乳房切除术后放疗相似。需要进行术前放疗与乳房切除术后放疗的随机试验,以准确确定和比较手术、肿瘤学和乳房重建结果,包括生活质量。
英国癌症研究中心,英国国家卫生研究院。